octreotide - CISMeF

Preferred Label : octreotide;

MeSH definition : A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.;

CISMeF synonym : 79517-01-4 (Octreotide acetate);

MeSH hyponym : sandostatine; octreotide acetate; SMS 201-995; SMS 201 995; SMS 201995; SM 201-995; SM 201 995; SM 201995; Sandoz 201-995; Sandoz 201 995; Sandoz 201995; Compound 201-995; Compound 201 995; Compound 201995; SAN 201-995; SAN 201 995; SAN 201995; Octreotide Acetate Salt; Sandostatin;

MeSH CAS label : L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2-7)-disulfide, (R-(R*,R*))-;

MeSH Related Number : octreotide acetate; 83150-76-9 (Octreotide); 75R0U2568I;

Registry Number MeSH : 83150-76-9;

Related CAS MeSH : 75R0U2568I (Octreotide acetate);

Wikipedia link : https://en.wikipedia.org/wiki/Octreotide;

Is substance : O;

UNII : RWM8CCW8GP;

InChIKey : DEQANNDTNATYII-OULOTJBUSA-N;

Details

Origin ID

D015282;

UMLS CUI

C0028833;

ATC code(s)
- octreotide [ATC Code]
- technetium (99mTc) hynic-octreotide [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
CISMeF manual mappings
- Octreotide adverse reaction (disorder) [SNOMED CT concept]
Currated CISMeF NLP mapping
- Octreotide [ICD-11 Extension code]
- Octreotide [LOINC component]
- Octreotide [ICHI extension code]
- Octreotide [NCIt concept]
- Octreotide (substance) [SNOMED CT concept]
- Product containing octreotide (medicinal product) [SNOMED CT concept]
Pharmacological action(s)
- antineoplastic agents, hormonal [MeSH Descriptor]
- gastrointestinal agents [MeSH Descriptor]
Record concept(s)
- SMS 201-995 [MeSH concept]
- octreotide [MeSH concept]
- octreotide acetate [MeSH concept]
- sandostatine [MeSH concept]
Related MeSH Supplementary Concept(s)
- (PnAO-(D)Phe(1))octreotide [MeSH Supplementary Concept]
- (technetium 99m-EDDA-tricine-HYNIC(0)-Nal(1)-Thr(8))octreotide [MeSH Supplementary Concept]
- 1,2-distearoylglycero-3-phosphoethanolamine-N-(methoxy(polyethylene glycol)-2000)octreotate [MeSH Supplementary Concept]
- 111In-DOTA-TOC [MeSH Supplementary Concept]
- 111In-octreotate, DOTA(0)-Tyr(3)-Thr(8)- [MeSH Supplementary Concept]
- 111In-octreotide, DTPA(0)- [MeSH Supplementary Concept]
- 111indium-DOTA, Tyr(3)-octreotate [MeSH Supplementary Concept]
- 177Lu-DOTA-octreotate [MeSH Supplementary Concept]
- 177Lu-octreotate [MeSH Supplementary Concept]
- 177Lu-octreotide, DOTA(0)-Tyr(3)- [MeSH Supplementary Concept]
- 3-Tyr-octreotide [MeSH Supplementary Concept]
- 4-nitrobenzo-2-oxa-1,3-diazol-octreotide [MeSH Supplementary Concept]
- 64Cu-DOTATATE [MeSH Supplementary Concept]
- 64Cu-SARTATE [MeSH Supplementary Concept]
- 68Ga-DOTA-octreotide [MeSH Supplementary Concept]
- 68Ga-octreotide, DOTA(0)-Tyr(3)- [MeSH Supplementary Concept]
- 90Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)- [MeSH Supplementary Concept]
- 90Y-octreotide, DOTA-Tyr(3)- [MeSH Supplementary Concept]
- 99mTc-octreotide [MeSH Supplementary Concept]
- AMBF3-TATE [MeSH Supplementary Concept]
- Al18F-NOTA-octreotide [MeSH Supplementary Concept]
- DOTA-Tyr(1)-octreotate [MeSH Supplementary Concept]
- DTPA-benzyl-acetamido-D-Phe(1),Tyr(3)-octreotide [MeSH Supplementary Concept]
- EE 581 [MeSH Supplementary Concept]
- Ga(III)-DOTATOC [MeSH Supplementary Concept]
- RC 121 [MeSH Supplementary Concept]
- SDZ 204-090 [MeSH Supplementary Concept]
- SDZ 215-811 [MeSH Supplementary Concept]
- SDZ 223228 [MeSH Supplementary Concept]
- SDZ CO 611 [MeSH Supplementary Concept]
- Y-DOTA-t-GA-tate [MeSH Supplementary Concept]
- Y-DOTAGA-tate [MeSH Supplementary Concept]
- copper 1,4,8,11--tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid-octreotide [MeSH Supplementary Concept]
- copper-1,4,8,11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid-octreotate [MeSH Supplementary Concept]
- desferrioxamine B-succinyl-phenylalanine(1)-octreotide [MeSH Supplementary Concept]
- edotreotide [MeSH Supplementary Concept]
- edotreotide lutetium LU-177 [MeSH Supplementary Concept]
- indium-111-octreotide [MeSH Supplementary Concept]
- lutetium Lu 177 dotatate [MeSH Supplementary Concept]
- octreotate, maltotriose-iodotyrosyl(3)- [MeSH Supplementary Concept]
- octreotide, CPTA-Phe(1)- [MeSH Supplementary Concept]
- octreotide, DOTA-Phe(1)- [MeSH Supplementary Concept]
- octreotide, DOTA-Tyr(3)- [MeSH Supplementary Concept]
- octreotide, TETA-Phe(1)- [MeSH Supplementary Concept]
- octreotide, iodoTyr(3)- [MeSH Supplementary Concept]
- octreotide-conjugated paclitaxel [MeSH Supplementary Concept]
- phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-threonyl-cysteinyl-N-naphthylalanine amide [MeSH Supplementary Concept]
- sandostatinLAR [MeSH Supplementary Concept]
- technetium 99m 6-hydrazinopyridine-3-carboxylic acid-Ser3-octreotate [MeSH Supplementary Concept]
- technetium 99m EDDA-tricine-HYNIC-Tyr(3)-octreotate [MeSH Supplementary Concept]
- technetium tc 99m (EDDA-HYNIC)octreotate [MeSH Supplementary Concept]
- technetium tc 99m 6-(4-thioureabenzyl)-3,3,9,9-tetramethyl-4,8-diazaundecane-phenylalanine(1)-octreotide [MeSH Supplementary Concept]
- technetium tc 99m cyclopentadienyltricarbonyloctreotide [MeSH Supplementary Concept]
- technetium tc 99m hydrazinonicotinyl-Tyr(3)-Thr(8)-octreotide [MeSH Supplementary Concept]
- technetium tc 99m hydrazinonicotinyl-Tyr(3)-octreotide [MeSH Supplementary Concept]
- technetium tc 99m-tricine-hydrazinonicotinyl-Phe(1)-Tyr(3)-octreotide [MeSH Supplementary Concept]
- yttrium cyclohexyldiethylenetriaminepentaacetic acid-octreotide [MeSH Supplementary Concept]
See also inter- (CISMeF)
- Poisoning caused by oral sulfonylurea derivative (disorder) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Hormone [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Octreotide [ICD-11 Extension code]
- Octreotide [NCIt concept]
- Octreotide [LOINC component]
- Octreotide (substance) [SNOMED CT concept]
- Product containing octreotide (medicinal product) [SNOMED CT concept]
- octreotide [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients